ofa tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says One GLP-1 Drug May Be

Individual Variability : Each person may respond differently to peptide therapy

J Neurosci 32:143150 Zhu Y, Antony JM, Martinez JA, Glerum DM, Brussee V, Hoke A, Zochodne D, Power C (2007) Didanosine causes sensory neuropathy in an HIV/AIDS animal model: impaired mitochondrial and neurotrophic factor gene expression

Dual-acting oral GLP-1s are not yet available, but they are expected in the future

In clinical studies, it was shown to lower the risk of heart attack, stroke, or death due to heart problems in certain people by 26%

The body is transforming in exactly the right direction

The same is true of semaglutide